These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 26860026)

  • 1. ANESTHESIA MANAGEMENT IN AN INFANT WITH GLYCOGEN STORAGE DISEASE TYPE II (POMPE DISEASE).
    Al Atassi A; Al Zughaibi N; Naeim A; Al Basha A; Dimitriou V
    Middle East J Anaesthesiol; 2015 Oct; 23(3):343-6. PubMed ID: 26860026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiac arrhythmias following anesthesia induction in infantile-onset Pompe disease: a case series.
    Wang LY; Ross AK; Li JS; Dearmey SM; Mackey JF; Worden M; Corzo D; Morgan C; Kishnani PS
    Paediatr Anaesth; 2007 Aug; 17(8):738-48. PubMed ID: 17596219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anaesthetic management of infants with glycogen storage disease type II: a physiological approach.
    Ing RJ; Cook DR; Bengur RA; Williams EA; Eck J; Dear Gde L; Ross AK; Kern FH; Kishnani PS
    Paediatr Anaesth; 2004 Jun; 14(6):514-9. PubMed ID: 15153218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Perioperative management of children with glycogen storage disease type II-Pompe disease.
    Bosman L; Hoeks SE; González Candel A; van den Hout HJM; van der Ploeg AT; Staals LM
    Paediatr Anaesth; 2018 May; 28(5):428-435. PubMed ID: 29575534
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [A case report of anesthesia for a child with Pompe's disease (glycogen storage disease type II)].
    Sakakibara M; Teramoto Y; Aoyama T; Takahashi T; Hara M; Maseki M; Yamaguchi S; Nakata J
    Masui; 2009 Feb; 58(2):219-22. PubMed ID: 19227183
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Anesthetic management for a child with pompe disease].
    Sato Y; Yamaguchi K; Miwa T; Hiroki K
    Masui; 2007 Mar; 56(3):324-5. PubMed ID: 17366920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved efficacy of gene therapy approaches for Pompe disease using a new, immune-deficient GSD-II mouse model.
    Xu F; Ding E; Liao SX; Migone F; Dai J; Schneider A; Serra D; Chen YT; Amalfitano A
    Gene Ther; 2004 Nov; 11(21):1590-8. PubMed ID: 15356673
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pompe disease (glycogen storage disease type II): clinical features and enzyme replacement therapy.
    van der Beek NA; Hagemans ML; van der Ploeg AT; Reuser AJ; van Doorn PA
    Acta Neurol Belg; 2006 Jun; 106(2):82-6. PubMed ID: 16898258
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ventricular fibrillation in a patient with Pompe disease: a cautionary tale.
    Desena HC; Brumund MR; Superneau D; Snyder CS
    Congenit Heart Dis; 2011; 6(4):397-401. PubMed ID: 21392261
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regional anesthetic techniques are an alternative to general anesthesia for infants with Pompe's disease.
    Walker RW; Briggs G; Bruce J; Fletcher J; Wraith ED
    Paediatr Anaesth; 2007 Jul; 17(7):697-702. PubMed ID: 17564654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of immune tolerance induction in restoration of the efficacy of ERT in Pompe disease.
    Lacaná E; Yao LP; Pariser AR; Rosenberg AS
    Am J Med Genet C Semin Med Genet; 2012 Feb; 160C(1):30-9. PubMed ID: 22253234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Infantile Pompe disease on ERT: update on clinical presentation, musculoskeletal management, and exercise considerations.
    Case LE; Beckemeyer AA; Kishnani PS
    Am J Med Genet C Semin Med Genet; 2012 Feb; 160C(1):69-79. PubMed ID: 22252989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [A case of Pompe disease treated with acid alpha-glucosidase].
    Kapica-Topczewska K; Tarasiuk J; Kułakowska A; Drozdowski W
    Neurol Neurochir Pol; 2008; 42(4):353-7. PubMed ID: 18975241
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Infantile-onset Pompe disease: a diagnosis not to miss.
    Dixon CA; Anderson JB; Ruddy RM; Cripe LH
    Pediatr Emerg Care; 2010 Apr; 26(4):293-5. PubMed ID: 20386415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Severe course of glycogen storage disease type II (Pompe's disease) without development of cardiomegalia.
    Ullrich K; Gröbe H; Korinthenberg R; von Bassewitz DB
    Pathol Res Pract; 1986 Oct; 181(5):627-32. PubMed ID: 2947052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enzyme replacement therapy in classical infantile pompe disease: results of a ten-month follow-up study.
    Klinge L; Straub V; Neudorf U; Voit T
    Neuropediatrics; 2005 Feb; 36(1):6-11. PubMed ID: 15776317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cognitive and adaptive functioning of children with infantile Pompe disease treated with enzyme replacement therapy: long-term follow-up.
    Spiridigliozzi GA; Heller JH; Kishnani PS
    Am J Med Genet C Semin Med Genet; 2012 Feb; 160C(1):22-9. PubMed ID: 22253038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Infantile-onset glycogen storage disease type II (Pompe disease): report of a case with genetic diagnosis and pathological findings.
    Teng YT; Su WJ; Hou JW; Huang SF
    Chang Gung Med J; 2004 May; 27(5):379-84. PubMed ID: 15366815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of respiratory muscle training (RMT) in children with infantile-onset Pompe disease and respiratory muscle weakness.
    Jones HN; Crisp KD; Moss T; Strollo K; Robey R; Sank J; Canfield M; Case LE; Mahler L; Kravitz RM; Kishnani PS
    J Pediatr Rehabil Med; 2014; 7(3):255-65. PubMed ID: 25260508
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Remarkably low fibroblast acid α-glucosidase activity in three adults with Pompe disease.
    Wens SC; Kroos MA; de Vries JM; Hoogeveen-Westerveld M; Wijgerde MG; van Doorn PA; van der Ploeg AT; Reuser AJ
    Mol Genet Metab; 2012 Nov; 107(3):485-9. PubMed ID: 23000108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.